Smoking Cessation—Part III: Pharmacotherapy of Smoking Cessation
نویسندگان
چکیده
منابع مشابه
Pharmacotherapy of smoking cessation.
Tobacco use is the number one cause of preventable diseases in the United States. Smoking accounts for more than 400,000 deaths yearly and 30% of all cancer deaths. Primary care physicians have access to 70% of smokers, approximately 60% of whom are perceived to be in excellent health. Recent advances in the pharmacotherapy of nicotine addiction, including nicotine nasal spray, nicotine inhaler...
متن کاملCost-effectiveness of pharmacotherapy for smoking cessation
Cost-effectiveness analysis, even with its inherent methodological problems, consistently shows that when smoking cessation interventions are effective they are invariably also cost-effective. This is largely due to their relative low cost and the big impact that stopping smoking has on health outcomes. This is also the case for pharmacotherapy for smoking cessation, including nicotine replacem...
متن کاملVarenicline: a novel pharmacotherapy for smoking cessation.
Varenicline is an orally administered small molecule with partial agonist activity at the alpha4beta2 nicotinic acetylcholine receptor. Varenicline was approved by both the US FDA and the European Medicines Agency of the EU in 2006 as an aid to smoking cessation. Subsequently, varenicline has been approved in over 80 other countries. Varenicline is almost entirely absorbed following oral admini...
متن کاملPharmacotherapy for smoking cessation during pregnancy.
As noted elsewhere in this issue, many pregnant women continue to smoke during pregnancy despite advice from health care providers that they should quit and/or because they have failed behavioral therapy. Continuing to smoke in the face of compelling reasons not to do so is an indication of addiction—that is, loss of control of drug use. Nicotine is responsible for addiction to cigarette smokin...
متن کاملEffects of Smoking and Smoking Cessation and Smoking Cessation Intervention
The threeto four-decade lag between peak in smoking prevalence and subsequent peak in smoking-related mortality was a major factor affecting public awareness of the substantial health hazards of tobacco use in developed countries (Lopez et al., 1994). This factor may be applicable to periodontal disease if this disease is chronically affected by smoking epidemic. We searched the literature elec...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: AAOHN Journal
سال: 2005
ISSN: 0891-0162
DOI: 10.1177/216507990505300805